Difference between revisions of "Busulfan (Myleran)"

Revision as of 16:53, 27 May 2021

General information

Class/mechanism: Bifunctional alkylating agent which produces guanine-adenine intrastrand crosslinks, inducing apoptosis.^[1]^[2]^[3]^[4]
Route: IV, PO
Extravasation: irritant

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape,UpToDate (courtesy of Lexicomp), or the prescribing information.^[1]

Diseases for which it is used

Diseases for which it was used

Multiple myeloma

Patient drug information

History of changes in FDA indication

6/26/1954: Initial FDA approval
1/23/2003: (earliest label available at Drugs@FDA) indicated for the palliative treatment of chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia.

Also known as

Brand names: Busulfex, Myleran

References

[insert-1] 1.0 ^1.1 ^1.2 Busulfan (Myleran) package insert

[2] Busulfan (Myleran) package insert (locally hosted backup)

[3] Busulfan (Busulfex) package insert

[4] Busulfan (Busulfex) package insert (locally hosted backup)

[5] Busulfan (Myleran) patient drug information (Chemocare)

[6] Busulfan (Myleran) patient drug information (UpToDate)

[1]

[2]

[3]

[4]

[5]

[6]

@@ Line 1: / Line 1: @@
 ==General information==
-Class/mechanism: Bifunctional alkylating agent which produces guanine-adenine intrastrand crosslinks, inducing apoptosis.<ref name="insert">[https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/09386slr023_myleran_lbl.pdf Busulfan (Myleran) package insert]</ref><ref>[[Media:Busulfan.pdf | Busulfan (Myleran) package insert (locally hosted backup)]]</ref><ref>[https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014lbl.pdf Busulfan (Busulfex) package insert]</ref><ref>[[Media:Busulfanbusulfex.pdf | Busulfan (Busulfex) package insert (locally hosted backup)]]</ref>
+Class/mechanism: Bifunctional alkylating agent which produces guanine-adenine intrastrand crosslinks, inducing apoptosis.<ref name="insert">[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bf456fc7-3a79-47f7-8acc-600b5e2f0dc2 Busulfan (Myleran) package insert]</ref><ref>[[Media:Busulfan.pdf | Busulfan (Myleran) package insert (locally hosted backup)]]</ref><ref>[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bf456fc7-3a79-47f7-8acc-600b5e2f0dc2 Busulfan (Busulfex) package insert]</ref><ref>[[Media:Busulfanbusulfex.pdf | Busulfan (Busulfex) package insert (locally hosted backup)]]</ref>
 <br>Route: IV, PO
 <br>Extravasation: [[irritant]]
@@ Line 18: / Line 18: @@
 ==Patient drug information==
-*[https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/09386slr023_myleran_lbl.pdf Busulfan (Myleran) package insert]<ref name="insert"></ref>
+*[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bf456fc7-3a79-47f7-8acc-600b5e2f0dc2 Busulfan (Myleran) package insert]<ref name="insert"></ref>
 *[http://chemocare.com/chemotherapy/drug-info/busulfan.aspx Busulfan (Myleran) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/busulfan.aspx Busulfan (Myleran) patient drug information (Chemocare)]</ref>
 *[http://www.uptodate.com/contents/busulfan-patient-drug-information Busulfan (Myleran) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/busulfan-patient-drug-information Busulfan (Myleran) patient drug information (UpToDate)]</ref>